A Spanish critical illness contract paid a Dutch cardiologist's fee schedule. That sentence sounds like the setup for a regulatory arbitration hearing, and in a way it was. The policyholder, a Spanish resident who had undergone heart surgery in the Netherlands in 2022, expected his Spanish insurer to reimburse the surgeon's charges. The insurer applied its own "reasonable and customary" benchmark, which was based on Spanish public hospital rates. The difference was substantial: the Dutch fee schedule was roughly three times higher. The case, mediated by an independent arbitrator in Madrid, never made headlines, but it illustrates a quiet problem: insurance products that look identical across borders often behave very differently when a claim is filed.

Why a Spanish Policy Paid a Dutch Doctor

The core issue was that critical illness definitions and fee benchmarks are not harmonised across EU member states. Spain's regulator allows insurers to define "reasonable and customary" based on domestic medical cost data. The Netherlands, which has a different healthcare funding model, has higher physician fees. The Spanish policy's language did not specify which country's fee schedule would apply if treatment occurred abroad. The policyholder assumed his European Health Insurance Card would cover the gap, but that card only covers emergency care at public rates—not a specialist's private fee.

The dispute wound its way through an internal appeals process. The insurer pointed to a clause stating that benefits were limited to "usual and customary charges in the region where treatment is received." The policyholder argued that the region was the Netherlands, not Spain. The insurer countered that the policy was sold in Spain, priced on Spanish risk data, and intended for Spanish medical costs. The independent mediator eventually split the difference, but the case exposed a vulnerability for anyone who buys a life or disability product in one country and later receives care in another.

There is no common EU framework for critical illness coverage terms. Each country's insurance regulator sets its own rules on benefit triggers, waiting periods, and fee schedules. The EU's Solvency II directive focuses on capital requirements, not policy language consistency. A 2023 European Insurance and Occupational Pensions Authority report noted that cross-border health insurance complaints had risen by roughly 15% over three years, with fee schedule mismatches being a common cause. This case is not isolated. Similar mismatches occur with disability income policies when a claimant moves to a country with different rehabilitation standards. For instance, a German disability policy might define total disability as inability to perform one's own occupation, while a Spanish policy might use a broader "any occupation" standard. A policyholder who buys in Spain and later works in Germany could find that a condition that would trigger a payout in Germany does not in Spain.

The Same Product, Two Different Markets

Consider term life insurance. A 40-year-old non-smoker in Spain might pay roughly €30 per month for a €200,000 policy with a 20-year term. In a US state like Texas, the same profile might pay around $45 per month for equivalent coverage. The difference stems from mortality assumptions, medical cost inflation, and regulatory overhead. US insurers factor in higher healthcare costs and more litigation risk, while Spanish insurers benefit from a public health system that reduces catastrophic medical expenses.

Whole life insurance tax treatment also diverges sharply. In Spain, policy cash values grow tax-deferred, but withdrawals are taxed as income. In many US states, policy loans are tax-free, and withdrawals up to basis are tax-free. A Spanish expatriate who moves to the US with a whole life policy may face unexpected tax bills when accessing cash value. The policy itself is the same, but the tax environment changes the outcome.

Disability waiting periods vary by jurisdiction. In Spain, a typical disability policy has a 90-day elimination period before benefits begin. In some US states, 30-day or 60-day periods are common, but premiums are higher. A policy sold in Spain with a 180-day waiting period might be cheaper, but a claimant who expects a shorter wait could face a financial gap. The product design reflects local market norms, not global standards.

Long-term care benefit triggers are another area of divergence. Some US policies trigger benefits when a policyholder cannot perform two of six activities of daily living. Spanish policies often use a different set of criteria, such as needing constant supervision due to cognitive impairment. A policyholder who moves from Spain to the US may find that a condition that qualifies for benefits in Spain does not meet the US policy's trigger, or vice versa.

To illustrate further, consider a hypothetical case: a 55-year-old Spanish woman buys a critical illness policy in Spain that covers heart attack, stroke, and cancer. She later moves to France and suffers a stroke. The Spanish policy defines stroke as "a neurological deficit persisting for more than 24 hours," while a comparable French policy might require a permanent deficit. Her Spanish policy pays out because the 24-hour threshold is met, but if she had bought a French policy, the claim might be denied. The same medical event yields different outcomes based on policy language.

How Underwriting Rules Shift the Risk

Medical questionnaire length differs across borders. In Spain, a typical application for a critical illness policy might ask 15 to 20 health questions. In the US, especially for fully underwritten policies, the questionnaire can run 40 to 50 questions, plus a paramedical exam. The Spanish approach relies more on the public health system's records, while US insurers often require blood and urine tests. This means the same applicant could be approved in Spain but declined in the US for a condition that was not asked about.

Genetic testing disclosure is required in some markets, not others. In the United Kingdom, a voluntary moratorium on using genetic test results for insurance applies for policies up to £500,000. In the US, the Genetic Information Nondiscrimination Act prohibits health insurers from using genetic information, but it does not apply to life, disability, or long-term care insurance. Some US states have additional restrictions. In Spain, genetic testing disclosure is not typically required, but if an applicant voluntarily discloses a test result, the insurer may use it. A person with a family history of Huntington's disease might buy a policy in Spain without disclosing a predictive test, but the same person moving to the US might face a higher premium or declination.

Pre-existing condition clauses vary by regulator. In Spain, a moratorium clause is common: conditions that existed in the five years before the policy start date are excluded for the first two years. In the US, many states have stricter rules, such as a 24-month look-back period for disability policies. A policyholder with a pre-existing condition that was not disclosed could find a claim denied in one market but paid in another. The risk is asymmetric: the policyholder may not know which rule applies until a claim is filed.

Moratorium underwriting versus full medical underwriting affects premium levels. Moratorium policies are cheaper because they shift the risk of undisclosed conditions to the policyholder. Full underwriting is more expensive but provides certainty. In Spain, moratorium policies are common for critical illness and disability. In the US, full underwriting is the norm for larger policies. A buyer who chooses a moratorium policy to save money might later discover that a condition they considered minor is excluded.

Another example: a 45-year-old man in Spain has a history of mild hypertension controlled by medication. He applies for a critical illness policy with a moratorium clause. The policy is issued without any exclusion for hypertension. Two years later, he suffers a heart attack. The insurer investigates and finds that the hypertension was present before the policy start date, but because the moratorium period has passed (two years), the claim is paid. In contrast, if he had bought a policy in the US with full underwriting, the hypertension would have been disclosed, and the policy might have been issued with a higher premium or a heart-related exclusion. The moratorium system allows the claim to be paid, but it also means the insurer priced the policy assuming some claims from undisclosed conditions will be paid.

Distribution Channel Distortions

Bancassurance dominates in Spain. Roughly 70% of life insurance policies are sold through banks, often as a bundled product with a mortgage. The bank's sales staff are not insurance specialists, and the product is often a simplified term life policy with limited features. In the US, independent agents and brokers control a large share of the market, especially for disability and long-term care insurance. The agent can compare products from multiple carriers and tailor coverage to the client's needs.

Commission structures influence product design. In Spain, bancassurance commissions are often embedded in the premium and not disclosed to the customer. The bank earns a recurring commission, which incentivises selling policies with higher premiums. In the US, commissions are typically front-loaded, meaning the agent earns a large percentage of the first year's premium. This can lead to a focus on products with high initial premiums, such as whole life, rather than lower-cost term insurance. The buyer's interests are not always aligned with the distributor's incentives.

Online direct sales are limited in some EU countries. In Spain, few insurers offer a fully online application for life or disability policies. Most require a face-to-face meeting or a phone interview. In the US, online direct sales have grown rapidly, with some carriers offering instant approval for term life policies up to $1 million. The lack of online options in some markets means higher distribution costs, which are passed on to consumers in the form of higher premiums.

Regulatory caps on commissions exist in certain states. For example, New York State caps life insurance commissions at a percentage of the premium, which varies by product and duration. Other states have no caps. In Spain, there is no explicit cap, but the insurance regulator imposes conduct-of-business rules that require commissions to be reasonable. The difference means that a policy sold in New York might have a lower commission load than the same policy sold in Florida, affecting the net premium paid by the consumer.

Regulatory Divergence in Claims Handling

Bad faith laws are stronger in the US than in most EU states. In the US, an insurer that unreasonably denies a claim can be sued for bad faith and may face punitive damages. In Spain, the concept of bad faith is less developed, and damages are typically limited to the policy benefit plus interest. A US policyholder who is denied a claim has more leverage to force a fair settlement. A Spanish policyholder in the same situation may have to accept the insurer's decision or pursue lengthy litigation.

Time limits for claim decisions vary widely. In Spain, insurers must respond to a claim within 40 days, but the clock can be paused if additional information is requested. In the US, many states require a decision within 30 days, with strict penalties for delays. For example, California requires insurers to accept or deny a claim within 40 days, and failure to do so can result in a penalty of 2% per month on the benefit amount. A policyholder in a state with strong prompt-pay laws is more likely to receive a timely payout.

Independent dispute resolution is not universal. In the Netherlands, policyholders can appeal a claim denial to an independent ombudsman, whose decision is binding up to a certain amount. In Spain, the insurance ombudsman exists but its decisions are not binding. The policyholder must go to court to enforce a claim. In the US, many states have a mediation program for insurance disputes, but the process varies. A policyholder who moves from the Netherlands to Spain might expect a similar level of consumer protection and be disappointed.

The Gabriel House fire in Massachusetts led to new safety and consumer rules for assisted living facilities, as reported in a July 2026 article on our site. The tragedy highlighted gaps in how assisted living policies are regulated. Massachusetts now requires facilities to have sprinkler systems and to disclose evacuation plans to residents. For insurers, these rules change the risk profile of assisted living policies. A policy sold in a state with weak safety regulations might have a higher claim frequency than one sold in Massachusetts, but the premium might not reflect that if the insurer uses national averages.

Trade-Offs and Considerations for International Buyers

When buying insurance across borders, there are inherent trade-offs. A policy that offers portability—allowing you to transfer coverage to a new country—may come with higher premiums or limited benefits. Conversely, a cheaper, non-portable policy may leave you exposed if you move. For example, some international health insurers offer worldwide coverage but with a cap on benefits based on the country of treatment. This can be a middle ground, but it adds complexity.

Another trade-off is between simplicity and coverage breadth. A simplified issue policy with few health questions is easier to buy but may have exclusions for common conditions. A fully underwritten policy offers more certainty but requires a longer application process and may be more expensive. Buyers who value convenience may opt for the simplified policy, but they should understand the risk of later claim denials.

Regulatory protections also vary. In the EU, the home country regulator oversees the insurer, but if you move, the new country's regulator has limited authority. In the US, state guaranty associations provide a safety net if an insurer fails, but coverage limits vary. A policyholder should consider which jurisdiction's protections matter most. For instance, a US expatriate in Spain might prefer a US-based policy because of stronger bad faith laws, but that policy may not cover treatment in Spain adequately.

Ultimately, there is no one-size-fits-all solution. The best choice depends on your lifestyle, risk tolerance, and willingness to read fine print. A buyer who plans to stay in one country for decades can safely buy a local policy. A buyer who moves frequently should invest time in understanding cross-border implications or consider a specialist international insurer.

The Unlikely Case That Exposes the System

The Spanish policy that paid a Dutch cardiologist's fee schedule was not a massive fraud or a systemic failure. It was a routine claim that went sideways because the policy's language was written for a single market. The policyholder did what many expatriates do: he bought insurance in his home country and assumed it would work wherever he received care. The insurer did what most insurers do: it applied the rules as written. The gap was not in the policy but in the assumption that insurance is portable across borders.

No EU directive harmonises medical fee benchmarks for insurance purposes. The European Health Insurance Card covers emergency care at public rates, but it does not apply to private treatment or to elective procedures. A policyholder who chooses a private specialist abroad is essentially uninsured for the difference between the local fee and the domestic benchmark. The case is a reminder that insurance is a contract governed by local law, not a universal passport.

The case also illustrates the limits of consumer protection. The policyholder had a right to appeal, but the appeals process favoured the insurer's interpretation. The mediator's split decision was a compromise, not a principle. The policyholder ended up paying roughly half the surgeon's fee out of pocket. The insurer paid the rest, but it also incurred legal costs that likely exceeded the savings from denying the full amount. Neither side was satisfied.

For a buyer, the lesson is to be aware that insurance products are not globally uniform. What works in one country may fail in another. The Spanish-Dutch case is unlikely to change the regulatory landscape, but it might change how one careful reader approaches a cross-border insurance purchase. As with any significant financial decision, consulting a qualified professional is advisable to navigate the complexities of cross-jurisdiction coverage.

Disclaimer: This article is for informational purposes only and does not constitute personalised insurance, legal, or financial advice. Coverage terms and regulatory protections vary by jurisdiction and policy. Readers should consult a qualified professional for advice specific to their situation.